Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Nkarta, Inc. NKTX

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-104.1M
$-89.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -104.1
-50M-100M
201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -28.9%
-10%-20%-30%
201920222025
Three returns, three denominators.

Each USD of equity lost 29 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -89.9
-50M-100M
201920222025

Total assetsUSD 404.2M
EquityUSD 312.3M
CashUSD 39.6M
Current ratio12.69×

Equity funds 77% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NKTX, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.0◌◌◌◌0.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0
EPS, diluted $−1.41−1.60−2.40−2.61−2.62−5.44−14.41
Dividend / sh $0.000.000.00◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−28.9−31.9−36.4−36.5−30.1——
Shares out B0.070.070.050.050.030.030.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image